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Abstract: In the contemporary medical model world, the proniosomal system has been serving as a
new drug delivery system that is considered to significantly enhance the bioavailability of drugs with
low water solubility. The application of this system can improve the bioavailability of aceclofenac that
is used for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing
spondylitis. The present study is intended to develop an optimized proniosomal aceclofenac formula
by the use of different carriers. Aceclofenac proniosomes have been prepared by slurry method, and
different carriers such as maltodextrin, mannitol, and glucose were tried. Prepared proniosomes
characterized by differential scanning calorimetry (DSC) analysis and Fourier transform infrared
(FTIR) analysis revealed the compatibility of the drug chosen with the ingredient added, powder
X-ray diffractometry (XRD) confirmed the amorphous phase of the prepared proniosomes, and finally,
the surfactant layer was observed by scanning electron microscopy (SEM). Aceclofenac physical state
transformations were confirmed with all formulas but maltodextrin proniosomes exhibited solubility
more than other formulations. HPLC method has been used to analyze the niosomes derived from
proniosomes in terms of their entrapment capability and drug content. The obtained results revealed
that aceclofenac proniosomes can be successfully prepared by using different carriers.
Keywords: aceclofenac; proniosomes; niosomes; carrier
1. Introduction
Vesicular systems are becoming leading systems in the field of drug delivery. Scientists are
increasingly working on these systems for improving their chemical, physical, and biological properties.
Liposomes, proliposomes, niosomes, proniosomes, transfersomes, and pharmacosomes are some
examples of the vesicular systems that are attracting much attention due to their flexibility to be tailored
for varied desirable purposes [1]. However, due to problems of stability and affordability, liposomes
and proliposomes have become unpopular among scholars [2]. According to Kakar et al. [3] niosomes
are considered cheaper and easier in terms of preparation if compared to liposomes, however fusion,
aggregation, sedimentation, and leakage on storage of such liquid dosage form caused a barrier in
front of this attractive vesicle.
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The contemporary proniosomes have been designed as a new vesicular system that possesses all
the advantages of niosomes and at the same time covering their disadvantages. A study conducted by
Hu and Rhodes (1999) [3] reported that proniosomes had advantages over liposomes and niosomes in
physical stability characters such as aggregation or fusion of vesicles and leaking of entrapped drugs
during long-term storage; also, less chemical degradation problems are encountered with proniosomes.
Consequently, it has attracted a lot of attention from researchers, who are focusing on its desirable
properties and applications to utilize the best characterizations of the vesicular systems [4].
Proniosomes are dry, free-flowing formulations of a surfactant-coated carrier that is suitable for
different routes of administration. Proniosomes are rehydrated by brief agitation in hot water to
form a multi-lamellar niosomal suspension. Niosomes derived from proniosomes have the ability
to enhance the bioavailability of either hydrophilic or lipophilic drugs [5]. A study was carried out
in which the vinpocetine proniosomes were prepared to analyze the effect of proniosomes on the
bioavailability of poorly soluble drugs. The study concluded that proniosomes could improve the
gastrointestinal absorption of vinpocetine and can provide an effective mean of delivering poorly
water-soluble drugs through the oral route [6]. Proniosomal system also exhibited an improvement in
the oral bioavailability of isradipine [7].
Niosomes are considered to be among the most suitable drug delivery systems discovered. It was
first used within the cosmetic delivery until the self-composition behaviour of the non-ionic surfactant
grabbed the attention of the pharmaceutical industry community.
Most of the studies that have addressed the behaviour of niosomes (the hydrated product of
proniosomes) indicated that the pharmacokinetics of the drug has changed drastically after the inclusion
into the vesicular carrier system. Drugs incorporated into the proniosomes have shown increased
solubility, which in turn resulted in enhanced absorption of the drug [3].
The main components of proniosomes are a surfactant, membrane stabilizer, and carrier [8].
Carriers permit the flexibility in the ratio of surfactant and other components incorporated. they
increase the surface area and enhance efficient loading e.g., sorbitol, mannitol, glucose, lactose [8,9].
Aceclofenac, a nonsteroidal anti-inflammatory drug (NSAID), has been indicated for various
painful indications and proved to be as effective as other NSAIDs with lower indications of
gastrointestinal adverse effects and, thus, resulted in greater compliance with treatment [10]. However,
due to its poor bioavailability, it has a limited presence in the market [11].
This research came as an attempt to prepare Aceclofenac proniosomes successfully, to study
different characterizations that can indicate the compatibility between ingredients and ensure the
physical phase transformation required for better drug solubility and, hence, absorption. However,
the ideal situation would be transforming proniosomes into niosomes whenever required to facilitate
the production of various dosage forms. This is why the proper method of proniosomes hydration
and factors affecting the hydration method of niosomes were studied. Also, this study focuses on
different carriers that can be used in such preparation, and comparison of different formulations that
have different carriers has been included.
2. Materials and Methods
2.1. Materials
Aceclofenac (COS Grade) was received as a gift sample from MEDA PHARMA (Dubai, United
Arab Emirates), Glucose (D) and Mannitol (Analar) was purchased from BDH (London, England),
Maltodextrin was purchased from Himedia Laboratories (Mumbai, India), Cholesterol was from MP
Biomedicals, LLC Span 60, Chloroform and Methanol were from Merck (Darmstadt, Germany) and
provided from IIUM, Malaysia. Disodium hydrogen phosphate, potassium dihydrogen phosphate,
and sodium chloride were procured from Fluka Analytical (Seelze, Germany). All chemicals used in
the study were of analytical grade.
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2.2. Methods
2.2.1. Preparation of Proniosomes
To prepare proniosomes, using the slurry method, three different carriers, namely maltodextrin,
glucose, and mannitol, were used [12]. The Aceclofenac was dissolved in a mixture (1:1) of chloroform
and methanol, then span 60 and cholesterol were dissolved in the same mixture. The completely
dissolved mixture was transferred to a 250 mL rounded flask containing the required amount of the
carrier. Then, the mixture was dried completely at 40 ◦C at 80 rpm under vacuum (16 mm Hg) using a
rotary flash evaporator (IKA, HB 10 Basic, Staufen, Germany).
In all the formulations, the composition of proniosomes preparation was dependent on the actual
dose of aceclofenac in the market, which is 100 mg. So, the composition of each formula was 100 mg
Aceclofenac, 500 mg span 60, 250 mg cholesterol; the carrier amount was kept at 66% w/w, which is
1500 mg per dose while the solvent mixture selected was methanol and chloroform in the ratio of
1:1 v/v.
2.2.2. Characterization of Proniosomes
Fourier Transform Infrared (FTIR) Analysis
To study the interaction between the different ingredients used in the formulation of proniosomes
a PerkinElmer UTAR and Two FT-IR spectrophotometers was employed [13]. The spectra was studied
and the peaks were analyzed for the interaction compatibility between the ingredients used and
ensured the absence of any interactions that change the drug molecule. Following this procedure,
the analysis of the pure drug, individual carrier, physical mixture of all ingredients, and the different
formulas was done. The samples were placed onto the surface of the Zinc selenide crystal and forced
gauge between 80–90 was applied with a pressure arm to ensure complete contact between samples
and the crystal to get the most accurate results. Finally, samples scanning by using PerkinElmer
Spectrum software (Model 1600, Massachusetts, US) were carefully conducted.
Differential Scanning Calorimetry (DSC) Analysis
Differential scanning calorimetry analysis was performed for pure aceclofenac, ingredients used,
and prepared proniosomes to record any melting point changes between the pure drug and the
formulations prepared. During this procedure, a measured amount of 6–10 mg of samples, namely
aceclofenac and optimized proniosomes formulations, were studied. The samples were placed in
aluminum crucibles and a reference was also used as a blank aluminum crucible, with a constant flow
of nitrogen at 20 mL/min. The scanning range was between 80–220 ◦C at a heating rate of 10 ◦C/min
and nitrogen was used as a purge gas by the use of Mettler Toledo (Ohio, USA) differential scanning
calorimeter, model DSC 3 [14].
Powder X-ray Diffractometry (XRD) Analysis
Using X-ray diffractometry (XRD), the crystallinity of the pure drug optimized proniosome
powder was measured with different carrier formulations using an X-ray diffractometer (X’ Pert PRO
PANalytical, West Borough, MA, USA) using CuKα radiation, nickel-filtered graphite monochromator
at 45 kV voltage, and 40 mA current with X’celerator detector for the purpose of measurement. The
samples were analyzed at small-angle X-ray scattering (SAXS) runs with the samples at 1◦ (2θ) min−1
from 3◦ to 60◦ (2θ). The crystallinity of the formulation was recorded, with peaks appearing after the
analysis with pure aceclofenac and formulations.
Scanning Electron Microscopy (SEM)
The Scanning electron microscopy (SEM) is a microscope that uses electron beams to produce
an accurate image of the sample, through focusing the beam of electrons to interact with the atoms
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producing various signals that are translated into information regarding the topography and the
composition of the sample. The topography (surface morphology), as well as the proniosome’s shape,
was studied using the SEM. Proniosome powders (FN1, FN2, and FN3) were examined separately by
SEM. Each sample was sprinkled over an aluminum stub using double-sided adhesive carbon tape,
then samples were stored under a vacuum until total removal of air in ‘Leica Em SCD005′ sputter
coater. The samples were sputter-coated with gold for 60 s to get a thickness of 14 nm. After the coating, the
surface morphology (roundness, smoothness, and formation of aggregates) of proniosomes was scanned
by Carl Zeiss AG-EVO® 50 Series under a magnification power that ranged from 50 x to 4k x [15].
Proniosomes Flowability
The flowability of the prepared proniosomes was found through the bulk density and the tapped
density of the proniosomal powder and then further related to Carr’s Index and Hausner Ratio
(HR) [16] Carr’s index. The following index was used to compute tapped and bulk density:
Carr’s index = (Tapped Density−Bulk Density/Tapped Density) × 100
Hausner ratio: This was calculated from tapped and bulk density using the following expression:
Hausner ratio = Tapped Density/Bulk Density.
2.2.3. Hydration of Niosomes and Optimization of Hydration Conditions by Using %EE
The proniosomes were prepared primarily to obtain niosomes with high entrapment efficiency
upon hydration. During this process, two factors were studied, the time and volume of the hydrating
medium in order to get the best conditions that should be applied for the hydration process. For
further studies, the niosomes with relatively higher entrapment efficiency were selected.
Following Solanki et al. [17] a 3-level factorial design was used [18] in which the volume of the
hydrating medium and time for hydration were the independent factors, while entrapment efficiency
was the response factor. The procedure for hydration of proniosomes was similar to what song and Tian
have mentioned with little modifications [6]. The proniosomes were hydrated using different volumes
of warm distilled water (80 ◦C) [2]. via hand shaking technique and niosomes kept for different timings
according to the experimental design mentioned in Table 1. The entrapment efficiency was evaluated
using indirect method. Entrapment efficiency was determined by using the centrifugation methods, in
which 1 mL of the prepared niosomal suspension was placed in the eppendorf for centrifugation by
using MESM EBA200 Table Top Centrifuge at 1400 rpm for 1 h. All supernatant was separated into
10 mL volumetric flasks, then the sediment was resuspended with distilled water twice to ensure that
all the unentrapped drug removed, all the supernatant was added together in the 10 mL volumetric
flask, and distilled water was added up to the mark (dilution factor = 10). Peak area was measured
using HPLC at 276 wavelength, and all formulas were done in triplicate [18].
Entrapment efficiency (EE%)
=
(Total amount of the drug in the dosage form unit−Amount of the unentrapped drug)×100
Total amount of the drug in the dosage form unit
Table 1. Three-level factorial design for optimization of hydration conditions.
Factor
Level Response
−1 0 1
The volume of hydration (mL) 10 15 20 Entrapment Efficiency
Time for hydration (min) 5 30 60
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Entrapment efficiency was determined, and results were analyzed using Microsoft Excel 2016 and
factorial ANOVA using IBM SPSS® statistics version 20, Chicago, IL, USA.
Amount of drug entrapment was measured using HPLC analysis [19,20]. HPLC method has been
done according to Paul [21]. The HPLC used was Shimadzu Prominence model CTO–10AS VP with
the column of Hypersil Gold, Dim (mm) 250 × 4.6, with the following chromatographic conditions,
mobile phase: Phosphate buffer, (pH 5.0): Acetonitrile with a ratio: 60:40 (v/v A and B), wavelength of
detection: 275 nm, flow rate 1.0 mL/min, and column oven temperature: 20 ◦C.
2.2.4. Characterization of Niosomes Derived from Proniosomes
Formulated proniosomes were hydrated with distilled water to get the niosomes and it was
further characterized by the following studies.
Vesicle Size, PDI, and Zeta Potential Measurements
The vesicle size was measured for the different niosome formulations using Zetasizer (NANO-S
Malvern Instrument, Worcestershire, UK). Then, 0.2 mL of niosomes were diluted in ultrapure water
(1.9 mL) and placed it in disposable sizing cuvette for measurement and samples run at the temperature
of 25 ◦C at 173◦ scattering angle. The average diameter and the polydispersity index (PDI) were
determined in triplicate.
Zeta potential for samples was measured using (NANO-Z Malvern Instrument, UK), the same
dilution of niosomal suspensions was used, and measurements were conducted on the same temperature
by the use of folded capillary cell for surface charge measurement [22].
Drug Content
For drug content measurement, 1 mL samples were obtained from the suspension and then
placed in 100 mL volumetric flask; the volume was made up by using propranolol. Then, the samples
were filtered through a 0.45 µm membrane and analyzed using HPLC, following the same method
mentioned above [11]. Results were analyzed and computed by using Microsoft Excel 2016.
Optical Microscopy
Optical microscope Leica DM750 (Wetzlar, Germany) with an attached camera was used for image
capturing, and niosomes were examined for their shape and size [23].
Statistical Analysis
All results were expressed as mean values ± SD (n = 3). For comparisons, one-way ANOVA test
was employed to determine statistically significant differences at a significance level of p < 0.05. These
tests were performed using IBM SPSS® statistics version 20.
3. Results and Discussion
3.1. Proniosomes Characterization
3.1.1. Fourier Transform Infrared (FTIR) Analysis
The FTIR results analyzed the IR spectrum of pure aceclofenac as in Figure 1A, which shows
many characteristic bands such as at 787.87 cm−1, 1139.09 cm−1, 1416.78 cm−1, 1437.92 cm−1, and
1715.40 cm−1; these results are in-line with Girma [18].
Meanwhile, the IR spectrum for the used carriers, as shown in Figure 1B–D, are as the following:
Glucose characteristic bands are at 994.19 cm−1, 614.55 cm−1, and 1020.89 cm−1, [24] maltodextrin
characteristic bands are at 995.64 cm−1 and 570.89 cm−1, which characterizes the anhydroglucose ring
stretching vibrations [25], and mannitol characteristic bands are at 1017.93 cm−1, 1077.75 cm−1, and
3282.78 cm−1 [26].
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carrier, (D) mannitol carrier, (E) formulation with glucose as a carri r (FN1), (F) formula with
maltodextrin as a carrier (FN2), and (G) formula with mannitol s a carrier (FN3).
The absence of any signific nt change in the IR spectrum pattern in the formulations containing
the drug and carrier, as in Figure 1E–G, confirms the absence of any interaction between the drug and
carrier used, hence it can be concluded that no interaction was determined between glucose, mannitol,
or maltodextrin and all the other components used, respectively.
3.1.2. Differential Scanning Calorimetry (DSC) Analysis
According to the DSC results, it has been observed that aceclofenac shows an endothermic
sharp peak at 155.15 ◦C with a peak value −33.47 Mw, as in Figure 2A, which is the melting point of
aceclofenac. Further, the melting points for different proniosomal preparations were recorded as the
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following, according to Figure 2B–D. FN1 recorded at 118.91 ◦C, 131.73 ◦C, and 138.73 ◦C with peaks
varied between −14.18 Mw to −19.01 Mw), while FN2 endothermic peaks are 121.64 ◦C, 133.14 ◦C, and
148.50 ◦C with peak values ranging between −15.53 Mw to –17.65 Mw, and FN3 has been recorded
at 156.04 ◦C with a peak value of –17.29 Mw. According to the peak values, it is clear that the sharp
peak is absent in all proniosomal formulations. Although, the endothermic peaks of the carriers are
for glucose at 155.8 ◦C [27], maltodextrin at 160 ◦C [15], and mannitol at 167.8 ◦C [28]. Consequently,
decreasing the melting point in proniosomes with glucose, maltodextrin, and mannitol, as shown in
Figure 2, revealed that a physical change occurred in aceclofenac proniosomal formulations. A research
study carried out by Veerarddy and Bobbala [7] revealed that the absence of a sharp peak explains that
the physical state of aceclofenac changes from crystalline to the amorphous phase, which proves the
enhanced solubility and faster dissolution.
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The dull peaks presented in Figure 2B–D for FN1, FN2, and FN3 could be attributed to the
existence of a degree of crystallinity due to the presence of the carriers, different carriers used as glucose
and maltodextrin, and also to the possibility that mannitol led to different dull endothermic peaks [14].
The study was only done on the formulated proniosomes as our concern is to observe the effect of
different carriers and their effect on the formulation.
3.1.3. Pow er X-ray Diffractomet y (XRD) Analysis
For properly assessing the degree of crystallinity of the proniosome constituents, powder X-ray
diffractometry (XRD) analysis was applied. It has been observed that the aceclofenac pure drug reached
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high peaks at 27◦ and 22◦, respectively, as in Figure 3A, and also shows some peaks from 10 θ to 20 θ,
which correspond to crystal nature of the aceclofenac at (2 θ) [29].
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According to different literature, carriers (glucose, maltodextrin, and mannitol) exhibited
differences in their crystallinity; glucose is considered a crystalline substance that has a sharp
peak at 18◦ (2 θ) [30], while maltodextrin exhibited no crystalline characteristic peaks; it has been
observed by many authors that if the peaks are not sharp, then the crystalline nature does not exist [31]
and mannitol is considered a highly crystalline substance with XRD high peaks at 9.6◦, 16.5◦, 18.0◦,
and 25.7◦ at (2 θ) [32].
Proniosomal formulations exhibited differences in the XRD analysis, as shown in Figure 3; FN1
and FN3 show a high peak, however these peaks are not the significant diffraction peaks of aceclofenac,
while maltodextrin gave a board curve. These findings support the hypothesis that proniosome
formulations have the ability to decrease the degree of crystallinity of the pure drug and enhance its
amorphous nature [33].
The presence of other sharp peaks in FN1 and FN3, as in Figure 3B,D, is due to the presence of
glucose and mannitol as a carrier, which has a crystalline state. From the crystalline behavior it is
inferred that there is entrapped in the bilayer membrane [6].
Results suggested that the degree of crystallinity significantly affected the solubility of the
proniosomes upon hydration. As shown in Figure 3C, FN2 exhibited an amorphous state much more
than FN1 and FN3 [34]. This means that maltodextrin is more soluble than other carriers.
Solubility of the carriers used may affect the dissolution and absorption of the drug after oral
administration. In vitro and in vivo studies should be carried out to confirm the effect of the carriers’
solubility on the drug absorption and, hence, bioavailability.
3.1.4. Scanning Electron Microscopy (SEM)
The topography (surface morphology) of aceclofenac, different carriers (glucose, maltodextrin,
and mannitol) and proniosomes formulations (FN1, FN2, and FN3) has been examined and revealed
that all carriers have been coated properly and adequately according to Figure 4B,D,E.
Pure aceclofenac is normally characterized by its crystal shape and smooth surface [35,36], while
glucose appeared with irregular shape, as in Figure 4B, maltodextrin had a spherical shape and was
characterized by holes spreading over its surface [37] while mannitol had a crystalline, cylindrical
shape, [38] but all carriers had a smooth surface, as shown in Figure 4A,C,E.
In this study, and according to the SEM results, proniosomes with glucose, maltodextrin, and
mannitol as carriers were obtained under the SEM with proper coating as in Figure 4B,D,E. A significant
difference between the carriers before coating and after coating were clearly observed.
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characterized by holes spreading over its surface [37] while mannitol had a crystalline, cylindrical 
shape, [38] but all carriers had a smooth surface, as shown in Figure 4A,C,E. 
In this study, and according to the SEM results, proniosomes with glucose, maltodextrin, and 
mannitol as carriers were obtained under the SEM with proper coating as in Figure 4B,D,E. A 
significant difference between the carriers before coating and after coating were clearly observed. 
All particles of the proniosomal formulations were completely coated with the surfactant as in 
Figure 4B,D,F. All images support the presence of the surfactant (span 60) layer with its rough surface 
over the particles that ensures a high entrapment efficiency of the niosomes derived from 
proniosomes after hydration. However, a thick layer of coating with the presence of granular surface 
suggests that proper hydration and agitation should be done for the proniosomes for ensuring proper 
niosomes formation [39]. According to Abd Elbary (2008), the degree of thickness does not negatively 
affect the entrapment efficiency [40]. 
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mannitol proniosomes as presented in Table 2. These results were supported by other researchers 
who have studied the flowability of proniosomes [41,42]. Also, using the slurry method for the 
preparation of proniosomes confirmed the extraction of a good flowable proniosome powder [8]. 
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Bulk  
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Density(g/mL) 
Carr’s 
Index 
Hausner’s 
Ratio  Type of Powder 
FN 1  0.36 ± 0.01 0.43 ± 0.01 16.6 ± 0 1.2 ± 0 Good Flowable 
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All particles of the proniosomal formulations were completely coated with the surfactant as in
Figure 4B,D,F. All images support the presence of the surfactant (span 60) layer with its rough surface
over the particles that ensures a high entrapment efficiency of the niosomes derived from proniosomes
after hydration. However, a thick layer of coating with the presence of granular surface suggests that
proper hydration and agitation should be done for the proniosomes for ensuring proper niosomes
formation [39]. According to Abd Elbary (2008), the degree of thickness does not negatively affect the
entrapment efficiency [40].
3.1.5. Powder Flowability
Flowability results indicate that all formulations were smooth with good flowability as in Table 2,
and non-significant differences were found between the flowability of glucose, maltodextrin, and
mannitol proniosomes as presented in Table 2. These results were supported by other researchers who
have studied the flowability of proniosomes [41,42]. Also, using the slurry method for the preparation
of proniosomes confirmed the extraction of a good flowable proniosome powder [8].
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Table 2. Representing the micromeritic properties of various proniosomal powder formulations, which
includes the bulk and tapped density of all formulations and their corresponding flowability according
to the Carr’s Index and Hausner’s ratio.
Formulation
Code
Bulk Density
(g/mL)
Tapped
Density (g/mL) Carr’s Index
Hausner’s
Ratio
Type of
Powder
FN 1 0.36 ± 0.01 0.43 ± 0.01 16.6 ± 0 1.2 ± 0 Good Flowable
FN 2 0.22 ± 0.04 0.28 ± 0.05 19.4 ± 1.3 1.24 ± 0.02 Fairly Flowable
FN 3 0.27 ± 0.02 0.38 ± 0.01 21.7 ± 2.5 1.31 ± 0.04 Fairly Flowable
A free flowable powder is considered a desirable outcome for further processing as a tablet or
capsules, as well as for packaging and pouring of the powder before its use [43].
3.2. Effect of Volume of Hydration and Time of Hydration
Our aim was to set entrapment efficiency as a dependent factor for the reason that proniosomes
are mainly judged on the basis of the entrapment efficiency. That is why one carrier has been chosen
randomly, which is maltodextrin, in order to optimize the hydration method of the proniosomes.
Hydration of proniosomes to niosomes is a significantly important factor that can possibly affect the
entrapment efficiency of the prepared niosomes. For this purpose, the volume of hydration and time
of hydration were studied to optimize the proper conditions of niosomes’ hydration.
According to the three-level experimental design in Table 1, entrapment efficiencies of nine
niosomal formulations (FM1–FM9) were compared. The results revealed that the volume of the
hydrating medium had a significant effect (p < 0.05) on EE%; the smaller the hydrating volume, the
better EE%, as shown in Table 3. These findings are in line with research that was done in 2010 by
Ruckman [44], which relates the high entrapment efficiency with a low volume of hydration and
concluded that leakage of the drug from niosomes increases with increase in the volume of hydration.
FM1 exhibited the highest EE%, which is 84%, in comparison to FM9 with 73% only.
Table 3. The following table illustrates the results of the three-level factorial design that has been studied
for optimization of hydration conditions; the factors were: The volume of the hydrating medium and
the time for hydration, and the response is their effect on the % of the entrapment efficiency.
Std Order Formulas The Volume ofHydrating Medium
Time for
Hydration
%Entrapment
Efficiency
1 FM 1 10 mL 5 min 84 ± 0.66
2 FM 2 10 mL 30 min 84 ± 0.75
3 FM 3 10 mL 60 min 82 ± 0.28
4 FM 4 15 mL 5 min 82 ± 0.29
5 FM 5 15 mL 30 min 78 ± 0.66
6 FM 6 15 mL 60 min 74 ± 0.74
7 FM 7 20 mL 5 min 81 ± 0.94
8 FM 8 20 mL 30 min 78 ± 0.61
9 FM 9 20 mL 60 min 73 ± 0.31
The present study confirms that time of hydration and volume of hydration has a significantly
negative effect (p < 0.05) on %EE according to Figure 5. With an increase in time and volume of
hydration, %EE decreases. At 10 mL hydration volume, the highest %EE was observed with no
significant difference (p > 0.05) between 5 min and 30 min of hydration, although other researchers
related the time of hydration with the entrapment efficiency by claiming that the more the niosomes
hydrated the more the drug entrapped [44].
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Figure 5. A graph representing the relationship between the results of the three-level factorial design
that has been studied for optimization of hydration conditions; the factors were: The volume of
the hydrating medium and the time for hydration, and the response is their effect on the % of the
entrapment efficiency.
The time of niosomes hydration has been differently mentioned in the early scholarly writings.
Most of the hydrated niosomes were kept for 2 min [45], while some researchers prefer to hydrate the
niosomes for 30 min [46] and other researches continued the hydration for 60 min [41]. Most of the
above-mentioned studies revealed that the time of hydration affects the shape and size of the vesicle
without any relation to the entrapment efficiency.
The findings of this research supported the idea of the study that because proniosomes should be
hydrated before administration, less waiting time will increase the applicability of the product and
will enhance patient compliance.
3.3. Characterization of Niosomes Derived from Proniosomes
3.3.1. Entrapment Efficiency
The results revealed a high percentage of aceclofenac that was entrapped in the niosomes formed;
mostly this is cons quent to t e use of span 60, whi h was chosen among all the other span types due
to its long alk l chain that result in higher ntra ment effic ency if compared with the other types of
span [47]. Regarding the type of c rri r used, non-sig ificant results were recorded b tween FN1, FN2,
and FN3, as illustrated in Table 4. No diffe ences were bserved betw en the diffe nt formulas that
have differe t carriers: Glucose, maltodextrin, an man itol. All carriers wer abl to give a high
entrapment efficiency with non-significant differences.
Table 4. Illustration of different characterization of the niosomes derived from proniosomes, which
includes the % of e trapment efficiency, size of the formed niosomes in nm, their Pdl a d Zeta potential,
and the % of the drug content in the niosomal suspensions formed.
Formulation
Code
%EE ± Standard
Deviation (SD)
Z-Average ±
SD (d.nm) Pdl
Zeta Potential
± SD (mV)
% of Drug
Content ± SD
FN 1 82 ± 0.5 5240 ±128 0.58 −46.3 ± 5.96 101 ± 0.65
FN 2 84 ± 0.66 4669 ± 20 0.7 −45.2 ± 5.14 98 ± 4
FN 3 84 ± 0.34 6403 ±25 1 −48.5 ± 5.06 96 ± 8
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The explanation beyond this finding could be due to the cholesterol used in the formula. As
cholesterol is considered as an amphiphilic molecule, it orients its OH group towards aqueous phase
and aliphatic chain towards surfactant’s hydrocarbon chain. Therefore, the multilamellar vesicles
could be formed with proper rigidity; the large volume of the aqueous hydrating medium used could
decrease the rigidity of the formed vesicles. Weak vesicles will have fewer tendencies to encapsulate
the drug and low entrapment efficiency would appear [48].
3.3.2. Vesicle size, PDI, and Zeta Potential Measurements
Vesicle size is a very critical attribute of lipidic nanocarriers, which affects stability, entrapment
efficiency, bioavailability, bio-distribution, and cellular uptake. Techniques used in the preparation of
such systems play a vital role in controlling vesicle size and distribution [48].
Membrane additives will significantly increase the stability of the produced niosomes. Each
component used in the system such as the surfactant, the membrane stabilizers, etc. will greatly affect
the morphology of the vesicles and the release of the drug from the vesicles.
According to our results, niosomes derived from proniosomes were analyzed with an average
diameter of 4–6 µm, in Table 4, which is considered a large vesicle in comparison to other niosomes;
the formation of a large vesicles came as a result of well hydration coupled with proper agitation
through hand shaking technique, which is considered applicable and simple. Increased agitation force
is the prime reason for the reduction of the vesicles size as in the sonication technique [49], although
sonication was used in a number of previously done research in the current area of interest [49].
The polydispersity index (currently known as dispersity index) is a measure of the distribution of
the particle size of a certain sample (heterogenicity of the size).
Our results revealed PDI values ranging 0.58–1, as in Table 4, which indicates variation in the
particle size distribution in all formulations [50]. Glucose shows the lowest PDI, which means the
highest homogeneity in the niosomal dispersion, while mannitol explores the highest value of the PDI,
which is 1.0 and indicates a heterogenous niosomal system.
Heterogenicity of the vesicle size in all niosomal formulations is due to the large size of the niosomes
prepared, which is the main reason for higher differences in the size distribution in comparison with
small vesicles. Meanwhile, vesicles with larger size have a higher tendency toward the drug entrapment.
The zeta potential results for all the niosomes formed (FN1, FN2, and FN3) were high and had
non-significant differences, as in Table 4. The absolute value of the zeta potential is an indicator of
the niosomes’ stability; the larger the zeta potential absolute value, the larger the amounts of surface
charge, which means increased repulsive interactions that led to more stable particles with a more
uniform size distribution [5,51]. Also, using cholesterol as a membrane stabilizer increases the rigidity
of the vesicular bilayer and results in decreasing the release of the drug from the niosomal system,
which enhances niosomes’ stability.
3.3.3. Drug Content
The drug content estimation within the niosomes is an essential step during the characterization
process; drug content ensures that every dose contains the amount of active ingredient intended with
little variation among other doses within a batch.
The niosomes prepared in this study revealed 96–100% drug content. These findings were in all
formulations that were prepared with different carriers. As shown in Table 4, non-significant differences
were observed between glucose, maltodextrin, and mannitol proniosomes. These findings indicate
the appropriateness of the method of preparation and support the hypothesis of the research, which
introduces different carriers in the proniosomes’ preparation without any significant differences [10].
3.3.4. Optical Microscope
The prepared niosomes appeared in Figure 6 as a large multilamellar vesicle with a spherical
shape. Similar to what has been mentioned by Sivaprasad et al., [8] no aggregation or agglomeration
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was observed under the microscope and smooth appearance was indicated. These results indicate the
preparation of well-hydrated niosomes and similar findings were also observed in the preparation of
indomethacin proniosomes [5].
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Figure 6. Optical microscope images that show the spherical shape of the formed niosomes after
hydration, and the distribution of these niosomes. The three different carriers were examined under
the microscope accordingly. (A) Glucose niosomes (FN1) Magnificatin (Mag) = 20 X, (B) maltodextrin
niosomes (FN2) Magnification (Mag) = 20 X, (C) mannitol niosomes (FN3) Magnification (Mag) = 20 X.
4. Conclusions
Aceclofenac proniosomes were prepared successfully by using different carriers such as glucose,
mannitol, and maltodextrin. Physicochemical characterization concluded the possibility of preparing
proniosomes by the use of differ nt carrie s, although maltodextrin exhibited th highest olubility
amo g ther carriers that may affe t t bio vail bility of the prepare formula. However, niosomal
characterization concluded non-significant differences in term of e trapment efficiency, ve icle size,
nd content uniformity. Providing different altern tives f r such formulati n gives a good opportunity
for the market to offer different products not only for aceclofenac, but also for any other drug with low
bioavailability. Proniosomes can be prepar d easily by the slurry method and niosomes derived from
proniosomes prepared exhibited a niosomal suspension with good stability, high entr pment efficiency
(84% ± 1), and (98% ± 4) drug content. Proniosomes can be hydr ted with a minimu am unt of
water, which is acceptable for adult administration, and only 5 min wait is required for the patient to
take their medication after hydration. The optimized aceclof ac proniosomes in this investigation
need to be further explored for bioavailability and stability stu ies.
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